Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 36 articles:
HTML format
Text format



Single Articles


    April 2018
  1. LUO Q, Wu X, Zhang Y, Shu T, et al
    ARID1A ablation leads to Multiple Drug Resistance in ovarian cancer via transcriptional activation of MRP2.
    Cancer Lett. 2018 Apr 13. pii: S0304-3835(18)30274.
    PubMed     Text format     Abstract available


    March 2018
  2. VAN HEETVELDE M, Van Bockstal M, Poppe B, Lambein K, et al
    Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Cancer Lett. 2018 Mar 23. pii: S0304-3835(18)30223.
    PubMed     Text format     Abstract available


  3. VIRANI NA, Thavathiru E, McKernan P, Moore K, et al
    Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30224.
    PubMed     Text format     Abstract available


    February 2018
  4. HASSAN W, Chitcholtan K, Sykes P, Garrill A, et al
    Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.
    Cancer Lett. 2018 Feb 9. pii: S0304-3835(18)30140.
    PubMed     Text format     Abstract available


  5. RICCIARDELLI C, Lokman NA, Sabit I, Gunasegaran K, et al
    Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30131.
    PubMed     Text format     Abstract available


    December 2017
  6. YANG Z, Jin P, Xu S, Zhang T, et al
    Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.
    Cancer Lett. 2017;415:20-29.
    PubMed     Text format     Abstract available


    November 2017
  7. TOMAR S, Plotnik JP, Haley J, Scantland J, et al
    ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
    Cancer Lett. 2017;414:190-204.
    PubMed     Text format     Abstract available


    October 2017
  8. YANG X, Wang CC, Lee WYW, Trovik J, et al
    Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30665.
    PubMed     Text format     Abstract available


  9. PISTOLLATO F, Calderon Iglesias R, Ruiz R, Aparicio S, et al
    The use of natural compounds for the targeting and chemoprevention of ovarian cancer.
    Cancer Lett. 2017 Oct 7. pii: S0304-3835(17)30619.
    PubMed     Text format     Abstract available


  10. SHU T, Li Y, Wu X, Li B, et al
    Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Cancer Lett. 2017 Oct 6. pii: S0304-3835(17)30609.
    PubMed     Text format     Abstract available


    September 2017
  11. LOUGHRAN EA, Phan RC, Leonard AK, Tarwater L, et al
    Multiparity Activates Interferon Pathways in Peritoneal Adipose Tissue and Decreases Susceptibility to Ovarian Cancer Metastasis in a Murine Allograft Model.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30581.
    PubMed     Text format     Abstract available


    July 2017
  12. SAKAI K, Ukita M, Schmidt J, Wu L, et al
    Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
    Cancer Lett. 2017 Jul 19. pii: S0304-3835(17)30439.
    PubMed     Text format     Abstract available


    May 2017
  13. LAKSHMINARASIMHAN R, Andreu-Vieyra C, Lawrenson K, Duymich CE, et al
    Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
    Cancer Lett. 2017 May 5. pii: S0304-3835(17)30312.
    PubMed     Text format     Abstract available


    April 2017
  14. SOKOLENKO AP, Savonevich EL, Ivantsov AO, Raskin GA, et al
    Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    Cancer Lett. 2017 Apr 1. pii: S0304-3835(17)30218.
    PubMed     Text format     Abstract available


    February 2017
  15. HU Y, Li D, Wu A, Qiu X, et al
    TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA.
    Cancer Lett. 2017 Feb 16. pii: S0304-3835(17)30109.
    PubMed     Text format     Abstract available


    January 2017
  16. DEAN M, Davis DA, Burdette JE
    Activin A Stimulates Migration of the Fallopian Tube Epithelium, an Origin of High-Grade Serous Ovarian Cancer, through Non-Canonical Signaling.
    Cancer Lett. 2017 Jan 20. pii: S0304-3835(17)30034.
    PubMed     Text format     Abstract available


    December 2016
  17. LUO T, Sun J, Zhu S, He J, et al
    Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts.
    Cancer Lett. 2016 Dec 30. pii: S0304-3835(16)30802.
    PubMed     Text format     Abstract available


  18. TODESCHINI P, Salviato E, Paracchini L, Ferracin M, et al
    Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts.
    Cancer Lett. 2016 Dec 22. pii: S0304-3835(16)30780.
    PubMed     Text format     Abstract available


  19. AUER K, Bachmayr-Heyda A, Aust S, Grunt TW, et al
    Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
    Cancer Lett. 2016 Dec 7. pii: S0304-3835(16)30739.
    PubMed     Text format     Abstract available


    November 2016
  20. JEONG JY, Kang HY, Kim TH, Kim GI, et al
    MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Cancer Lett. 2016 Nov 22. pii: S0304-3835(16)30705.
    PubMed     Text format     Abstract available


    September 2016
  21. YOU J, Liu J, Bao Y, Wang L, et al
    SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer.
    Cancer Lett. 2016 Sep 30. pii: S0304-3835(16)30574.
    PubMed     Text format     Abstract available


  22. LI Q, Zhang C, Chen R, Xiong H, et al
    Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30561.
    PubMed     Text format     Abstract available


    April 2016
  23. LUO Z, Wang Q, Lau WB, Lau B, et al
    Tumor microenvironment: The culprit for ovarian cancer metastasis?
    Cancer Lett. 2016 Apr 27. pii: S0304-3835(16)30274.
    PubMed     Text format     Abstract available


  24. MALEVA KOSTOVSKA I, Wang J, Bogdanova N, Schurmann P, et al
    Rare ATAD5 missense variants in breast and ovarian cancer patients.
    Cancer Lett. 2016 Apr 1. pii: S0304-3835(16)30209.
    PubMed     Text format     Abstract available


    March 2016
  25. TONG H, Ke JQ, Jiang FZ, Wang XJ, et al
    Tumor-associated macrophage-derived CXCL8 could induce ERalpha suppression via HOXB13 in endometrial cancer.
    Cancer Lett. 2016 Mar 24. pii: S0304-3835(16)30196.
    PubMed     Text format     Abstract available


  26. TANG S, Xiang T, Huang S, Zhou J, et al
    Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling.
    Cancer Lett. 2016 Mar 23. pii: S0304-3835(16)30194.
    PubMed     Text format     Abstract available


    January 2016
  27. AI Z, Lu Y, Qiu S, Fan Z, et al
    Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Cancer Lett. 2016 Jan 19. pii: S0304-3835(16)00021.
    PubMed     Text format     Abstract available


    December 2015
  28. GWAK H, Kim S, Dhanasekaran DN, Song YS, et al
    Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells.
    Cancer Lett. 2015 Dec 15. pii: S0304-3835(15)00722.
    PubMed     Text format     Abstract available


    November 2015
  29. SEO JA, Kim B, Dhanasekaran DN, Tsang BK, et al
    Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum ca ATPase activity in ovarian cancer cells.
    Cancer Lett. 2015 Nov 19. pii: S0304-3835(15)00697.
    PubMed     Text format     Abstract available


    September 2015
  30. THIBAULT B, Clement E, Zorza G, Meignan S, et al
    F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.
    Cancer Lett. 2015 Sep 23. pii: S0304-3835(15)00586.
    PubMed     Text format     Abstract available


  31. GORODNOVA TV, Sokolenko AP, Ivantsov AO, Iyevleva AG, et al
    High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    Cancer Lett. 2015 Sep 2. pii: S0304-3835(15)00569.
    PubMed     Text format     Abstract available


    August 2015
  32. ALTMAN MK, Alshamrani AA, Jia W, Nguyen H, et al
    Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.
    Cancer Lett. 2015 Aug 28. pii: S0304-3835(15)00541.
    PubMed     Text format     Abstract available


    July 2015
  33. HOVER LD, Young CD, Bhola NE, Wilson AJ, et al
    Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.
    Cancer Lett. 2015 Jul 30. pii: S0304-3835(15)00487.
    PubMed     Text format     Abstract available


  34. TANG MK, Wong AS
    Exosomes: Emerging biomarkers and targets for ovarian cancer.
    Cancer Lett. 2015 Jul 17. pii: S0304-3835(15)00456.
    PubMed     Text format     Abstract available


    March 2015
  35. CHEN S, Chen X, Xiu YL, Sun KX, et al
    MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression.
    Cancer Lett. 2015 Mar 25. pii: S0304-3835(15)00221.
    PubMed     Text format     Abstract available


    February 2015
  36. WANG H, Bao W, Jiang F, Che Q, et al
    Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma
    Cancer Lett. 2015 Feb 16. pii: S0304-3835(15)00132.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: